Supernus Pharmaceuticals (SUPN) Intangibles (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Intangibles data on file, last reported at $549.7 million in Q1 2026.

• Intangibles for Q1 2026 came in at $549.7 million, up 9.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $549.7 million (up 9.48% YoY), and the FY2025 annual result was $569.5 million, up 9.11% from the prior year.
• Intangibles slipped to $549.7 million in Q1 2026 per SUPN's latest filing, from $569.5 million in the prior quarter.
• Over five years, Intangibles peaked at $764.0 million in Q1 2022 and troughed at $481.3 million in Q2 2025.
• A 5-year average of $614.5 million and a median of $599.9 million in 2023 frame the typical range for Intangibles.
• The sharpest annual moves came in 2022 and 2024: Intangibles jumped 112.98% in 2022, then retreated 15.75% in 2024.
• A 5-year view of Intangibles shows it stood at $702.5 million in 2022, then declined by 14.6% to $599.9 million in 2023, then declined by 13.0% to $521.9 million in 2024, then gained by 9.11% to $569.5 million in 2025, then retreated by 3.47% to $549.7 million in 2026.
• Business Quant data shows SUPN's Intangibles at $549.7 million in Q1 2026, $569.5 million in Q4 2025, and $623.5 million in Q3 2025.